Literature DB >> 33457027

Disseminated M. bovis Infection and Vertebral Osteomyelitis following Immunotherapy for Bladder Cancer.

Harpreet S Gill1, Suhas P Dasari1, Sarbagya Pandit1, Thomas E Ritter1, Sushma B Raju1, Alexander R Chartier1, Pinky Jha1.   

Abstract

The use of BCG in immunotherapy for bladder cancer has been in practice for over 40 years. However, uncommon, serious complications can occur with the therapy. Here, we present a case of vertebral osteomyelitis secondary to dissemination of BCG following immunotherapy, an exceedingly rare presentation of an already rare complication.
Copyright © 2020 Harpreet S. Gill et al.

Entities:  

Year:  2020        PMID： 33457027      PMCID： PMC7785387          DOI： 10.1155/2020/6676163

Source DB:  PubMed          Journal:  Case Rep Infect Dis


  9 in total

1.  BCG-induced discitis and osteomyelitis in a patient with a history of bladder cancer.

Authors:  Cheryl L Heck; Gary T Schwartzbauer
Journal:  JAAPA       Date:  2019-05

2.  Mycobacterium bovis BCG causing vertebral osteomyelitis (Pott's disease) following intravesical BCG therapy.

Authors:  I S Aljada; J K Crane; N Corriere; D G Wagle; D Amsterdam
Journal:  J Clin Microbiol       Date:  1999-06       Impact factor: 5.948

Review 3.  Recombinant Mycobacterium bovis BCG for immunotherapy in nonmuscle invasive bladder cancer.

Authors:  K R Begnini; J H Buss; T Collares; F K Seixas
Journal:  Appl Microbiol Biotechnol       Date:  2015-03-21       Impact factor: 4.813

Review 4.  Mycobacterium bovis vertebral osteomyelitis as a complication of intravesical BCG use.

Authors:  Rima Abu-Nader; Christine L Terrell
Journal:  Mayo Clin Proc       Date:  2002-04       Impact factor: 7.616

5.  Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer.

Authors:  D L Lamm; P M van der Meijden; A Morales; S A Brosman; W J Catalona; H W Herr; M S Soloway; A Steg; F M Debruyne
Journal:  J Urol       Date:  1992-03       Impact factor: 7.450

6.  Human Tuberculosis Caused by Mycobacterium bovis in the United States, 2006-2013.

Authors:  Colleen Scott; Joseph S Cavanaugh; Robert Pratt; Benjamin J Silk; Philip LoBue; Patrick K Moonan
Journal:  Clin Infect Dis       Date:  2016-06-13       Impact factor: 9.079

7.  Mycobacterial Osteomyelitis of the Spine Following Intravesical BCG Therapy for Bladder Cancer.

Authors:  Charles E Mackel; Shane M Burke; Taylor Huhta; Ron Riesenburger; Simcha J Weller
Journal:  Cureus       Date:  2016-03-26

Review 8.  Bacillus Calmette-Guérin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature.

Authors:  María Asunción Pérez-Jacoiste Asín; Mario Fernández-Ruiz; Francisco López-Medrano; Carlos Lumbreras; Ángel Tejido; Rafael San Juan; Ana Arrebola-Pajares; Manuel Lizasoain; Santiago Prieto; José María Aguado
Journal:  Medicine (Baltimore)       Date:  2014-10       Impact factor: 1.889

9.  Bacillus Calmette-Guérin Cases Reported to the National Tuberculosis Surveillance System, United States, 2004-2015.

Authors:  Zimy Wansaula; Jonathan M Wortham; Godwin Mindra; Maryam B Haddad; Jorge L Salinas; David Ashkin; Sapna B Morris; Gail B Grant; Smita Ghosh; Adam J Langer
Journal:  Emerg Infect Dis       Date:  2019-03       Impact factor: 6.883
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.